尼特洛克通过抑制STAT3-AKT-MTOR生存信号来提高非小细胞肺癌的放射敏感性
Eun-Young Gong1, Hye Won Lee1, Hyunseung Oh2
1Department of Pathology, Keimyung University School of Medicine, Daegu 1095, Republic of Korea.
International journal of molecular sciences
|March 14, 2026
概括
抗微生物药物尼特素通过抑制STAT3信号来增强非小细胞肺癌 (NSCLC) 的辐射敏感性. 这种组合疗法促进癌细胞死亡和DNA损伤,提高了放射治疗的有效性.
科学领域:
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
- 分子生物学分子生物学
背景情况:
- 放射治疗对于非小细胞肺癌 (NSCLC) 治疗至关重要.
- 癌细胞通过生存信号通路对辐射产生抵抗力.
- STAT3是辐射暴露后细胞存活的关键调节者.
研究的目的:
- 调查一种STAT3抑制剂的尼特洛克索林是否可以增强NSCLC细胞中的放射敏感性.
- 阐明尼特素影响NSCLC辐射敏感性的机制.
主要方法:
- 研究了氧和辐射对NSCLC细胞活力的联合作用.
- 分析了关键的信号通路 (STAT3,AKT,mTOR) 和亡标记物 (p53,PARP,caspase-3).
- 评估了DNA损伤反应标记 (γ-H2AX,DNA-PKcs).
主要成果:
- 尼트로林显著增加了辐射诱导的细胞毒性,并减少了NSCLC细胞存活率.
- 尼트로林抑制了STAT3,AKT和mTOR的基底和辐射诱导的酸化.
- 组合疗法增强了细胞亡和放大了辐射诱导的DNA损伤.
结论:
- 尼特洛克因通过抑制STAT3-AKT-mTOR通路,在NSCLC中起到放射敏感剂的作用.
- 这种抑制促进了亡并增强了DNA损伤,改善了放射治疗的结果.
- 重新利用尼特洛克林显示了提高NSCLC治疗效率的潜力.
相关概念视频
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway
6.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.1K


